

HOUSE HEALTH COMMITTEE

VOTING MEETING

Tuesday, April 30, 2024

9:30 am 140 Main Capitol Building Harrisburg, PA

1. Call to Order

2. Attendance

3. HB2208 PN2930 (Frankel)

An Act amending the act of April 17, 2016 (P.L.84, No.16), known as the Medical Marijuana Act, in medical marijuana controls, further providing for laboratory; and, in Medical Marijuana Advisory Board, further providing for advisory board.

<u>A04176 (Frankel)</u> Provides for definitions and updated terminology throughout the bill. Provides for fees and timelines of regulations. Provides for research and development testing, audit testing, and clarifies inspections and corrective actions.

SB721 PN1147 (Schwank)

An Act establishing the Women, Infants and Children State Advisory Board.

HR397 PN2949 (Oberlander)

A Resolution recognizing the week of May 6 through 12, 2024, as "Women's Lung Health Week" in Pennsylvania.

- 4. Any other business that may come before the Committee
- 5. Adjournment

HOUSE OF REPRESENTATIVES DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:	HB2208 PN2930	Prepared By:	Dylan Lindberg
Committee:	Health		(717) 705-1875,6240
Sponsor:	Frankel, Dan	Executive Director:	Erika Fricke
Date:	1/8/2024		

A. Brief Concept

Improves oversight of Medical Marijuana testing laboratories.

C. Analysis of the Bill

House Bill 2208 amends the Medical Marijuana Act to improve oversight of approved testing laboratories.

Two Lab System

Removes the requirement that a grower/processor utilize a different lab for harvest testing and finished product testing (aka two-lab rule).

Standard Operating Procedures

Requirements

Laboratories are required to maintain standard operating procedures for validity of results testing, quality control, and sampling and testing procedures.

Labs must submit their standard operating procedures to the department at application for approval (or within 120 days if they are already approved before this act), renewal, and within 30 days of any substantial change.

DOH is required to inspect approved labs at least once a year to ensure they are adhering to their standard operating procedures. DOH can utilize an accreditation body to fulfill this requirement.

Penalties

If DOH finds the lab is not adhering to the approved standard operating procedure, the department must submit the findings to the lab. If the lab does not adhere to actions, it faces civil penalties as determined by the department.

The department maintains its ability to revoke or suspend a license if they find cause during the inspection.

Validity of Results Testing

Requirements

DOH is required, at least once a year, to ensure test results reported by labs are accurate using an established method. DOH can utilize an accredited proficiency test provider to fulfill this requirement. Any testing under this section must be separate from testing required as part of the accreditation process.

If a result is found invalid, the department is required to review the lab's standard operating procedures, conduct additional testing to understand any anomalies or unanticipated errors, and ensure the lab adheres to corrective actions.

If a lab does not adhere to corrective actions or does not participate, the lab is subject to civil penalties as determined by the department. The department maintains its ability to suspend or revoke a license for failure to maintain proper standards of accuracy, dishonest reporting, or repeated errors in conducting the required testing as prescribed in Title 28 Chapter 1171a.24.

Trend Analysis

DOH can utilize the seed-to-sale tracking system to conduct trend analysis as part of the lab oversight.

Addition to the Board

This legislation adds a member with expertise in laboratory science to the Medical Marijuana Advisory Board.

Accreditation

DOH is required to determine the level of accreditation labs must meet. If the department requires additional accreditation than what the lab has already achieved, they must give reasonable time to gain the new accreditation.

State Lab

DOH may establish their own reference lab or enter into a memorandum of understanding with the Department of Agriculture to use an existing lab as a MMJ reference lab.

The reference lab may be used to create a reference library to develop testing methodologies and standard operating procedures, conduct compliance and proficiency testing, and remediate problems.

Regulations and Staff

DOH is required to issue regulations to oversee labs and to hire a sufficient staff with expertise in this subject matter to carry out the oversight.

Effective Date:

90 days.

G. Relevant Existing Laws

The Medical Marijuana Act of 2016 provides for approved testing labs.

Title 28 Chapter 1171a provides for regulation of approved testing labs.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

n/a

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

HOUSE OF REPRESENTATIVES DEMOCRATIC COMMITTEE AMENDMENT REPORT

HB2208 - PN2930 (Frankel, Dan)

Improves oversight of Medical Marijuana testing laboratories.

A-04176 (Frankel, Dan)

Provides definitions and replaces terminology throughout the bill.

Provides for an initial application fee of \$250 and an annual fee of \$125.

Allows labs to conduct testing for research and development.

Allows the department to perform audit testing, such as requiring a third-party lab or another approved lab to retest a product and compare results.

Requires labs to submit proposed modifications to SOPs within 30 days.

Specifies the department can conduct announced and unannounced inspections and require corrective actions to be approved by the department. The department must approve or deny a corrective action plan within 30 days. If a plan is denied, the department must state the reasons and the lab can resubmit a revised corrective action plan.

Clarifies violations are subject to civil penalties and the department can revoke or suspend a license.

Specifies trend analysis may be used for: compliance, the functionality of testing standards, to release de-identified data, and to post testing data on the departments website.

Requires the department to submit temporary regulations within 6 months of the effective date and provide updated guidance along with the regs.

Ensures the additional member of the board is not affiliated with an approved lab.

4/29/24, 12:57 PM

Bill Analysis - Preview

LEGISLATIVE REFERENCE BUREAU

AMENDMENTS TO HOUSE BILL NO. 2208 Sponsor: Frankel #23 Printer's No. 2930

Amend Bill, page 1, lines 12 through 15, by striking out "in 1 medical" in line 12 and all of lines 13 through 15 and inserting 2 in preliminary provisions, further providing for definitions; 3 in medical marijuana controls, further providing for 4 electronic tracking and for laboratory; and, in Medical 5 Marijuana Advisory Board, further providing for advisory 6 7 board. Amend Bill, page 1, lines 18 through 24; pages 2 through 9, 8 lines 1 through 30; page 10, lines 1 through 11; by striking out 9 all of said lines on said pages and inserting 10 Section 1. Section 103 of the act of April 17, 2016 (P.L.84, 11 No.16), known as the Medical Marijuana Act, is amended by adding 12 definitions to read: 13 Section 103. Definitions. 14 The following words and phrases when used in this act shall 15 have the meanings given to them in this section unless the 16 context clearly indicates otherwise: 17 "Accreditation body." An organization which meets all of the 18 following criteria: 19 (1) Certifies the competency, expertise and integrity of 20 a laboratory and operates in conformance with the most recent 21 version of International Organization for Standardization 22 ISO/IEC 17011 adopted by the department through publication 23 in the Pennsylvania Bulletin after review. 24 (2) Determines a laboratory's compliance with and 25 conformance to the relevant standards established by the 26 International Organization for Standardization, including 27 ISO/IEC 17025. 28 (3) Is a signatory to the International Accreditation 29 Cooperation Mutual Recognition Arrangement for Testing. 30 (4) Is not affiliated with a laboratory applicant for 31 which it has or will issue a certificate of accreditation. 32 (5) Is not affiliated with, owned by, operated by or 33 financed by a medical marijuana organization. 34 * * * 35

<pre>1 "Approved laboratory." An independent laboratory approved by 2 the department, in accordance with section 704, to identify. 3 collect, handle and conduct tests on medical marijuana samples 4 from a grower/processor, as part of the quality assurance 5 testing and on medical marijuana samples from the department. 7 "Cooperative laboratory." A public or private independent 8 laboratory that identifies, collects, handles and conduct sets 9 on medical marijuana samples on behalf of the department. The 9 term does not include an approved laboratory. 8 * * * 9 "Independent laboratory." A laboratory that: 9 (1) Is not owned, operated or affiliated with a medical 9 marijuana organization. 9 (2) Does not employ a principal, financial backer. 9 (2) Does not employ a principal, financial backer. 10 operator or employee of a medical marijuana organization. 13 Is recognized by an accreditation body to test and 14 free from commercial, financial or other pressures that may 15 influence the results of the testing and evaluation process. 15 * * * 16 Section 2. Sections 701(c) and 704 of the act are amended to 17 read: 17 read: 18 Section 701. Electronic tracking. 17 * * * 19 Section 704. [Laboratory.] Laboratories. 10 (1) General testingA grower/processor shall contract 19 what one or more independent laboratories to test the medical 10 marijuana produced by the grower/processor. The department shall 10 approve a laboratory under this subsection and require that the 11 laboratory report testing results in a manner as the department 18 shall determine, including requiring a test at harvest and a 19 test at final processing. The possession by a laboratory of 10 medical marijuana product derived from a harvest batch and 21 test at final processor shall contract 22 shall determine, including requiring a test at harvest and a 22 test at final processor shall retain a sample from each 23 medical marijuana product derived from a harvest batch and 24 request that a sample be identified and collected by a 2 laboratory approved</pre>	1	
<pre>collect, handle and conduct tests on medical marijuana samples from a grower/processor, as part of the quality assurance testing and on medical marijuana samples from the department. *** "Cooperative laboratory." A public or private independent laboratory that identifies, collects, handles and conducts tests on medical marijuana samples on behalf of the department. The term does not include an approved laboratory. *** "Independent laboratory." A laboratory that: (1) Is not owned, operated or affiliated with a medical marijuana organization. (2) Does not employ a principal, financial backer, operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 2. Sections 701(c) and 704 of the act are amended to read: (a) Access[Information] Except as provided in section 7104(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory</pre>		Approved laboratory." An independent laboratory approved by
<pre>from a grower/processor, as part of the quality Julia Samples testing and on medical marijuana samples from the department. *** "Cooperative laboratory." A public or private independent laboratory that identifies, collects, handles and conducts tests on medical marijuana samples on behalf of the department. The term does not include an approved laboratory. *** "Independent laboratory." A laboratory that: (1) Is not owned, operated or affiliated with a medical marijuana organization. (2) Does not employ a principal, financial backer, operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. *** Co Access[Information] Except as provided in section 7D3(1). Electronic tracking. *** Section 701. Electronic tracking. *** Section 704. [Laboratory.] Laboratories. (a) General testing A grower/processor shall contract with one or more independent this order the subsection and require that the laboratory report testing results in a maner as the department shall determine, including requiring a test at harvest and a test at final procession. The possession by a laboratory of marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product 's optency and purity. A grower/processor shall contract wit extended by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory approved under subsection (a) from each process lot to perform stability testingA laboratory shall perform stability testing to ensure the medical marijuana product 's optency and purity. A grower/processor shall retain a sample from each is the department subsection (a) from each process lot is perform stability testingA laboratory shall perform stability testing to ensure the</pre>		the department, in accordance with section 704, to identify,
<pre>5 testing and on medical marijuana samples from the department. 6 * * * 7 "Cooperative laboratory." A public or private independent 1 laboratory that identifies, collects, handles and conducts tests 9 on medical marijuana samples on behalf of the department. The 1 term does not include an approved laboratory. 1 * * * 1 "Independent laboratory." A laboratory that: 1 (1) Is not owned, operated or affiliated with a medical 1 marijuana organization. 1 (2) Does not employ a principal, financial backer, 1 operator or employee of a medical marijuana organization. 1 (3) Is recognized by an accreditation body to test and 1 free from commercial, financial or other pressures that may 2 influence the results of the testing and evaluation process. 2 Section 701. Electronic tracking. 2 * * * 2 Section 701. Electronic tracking. 2 * * * 2 Section 701. Electronic tracking. 2 * * * 2 Section 704. [Laboratory.] Laboratories. 3 [(a) General testing A grower/processor shall contract 4 with one or more independent the aboratories to test the medical 2 marijuana produced by the grower/processor. The department shall 3 approve a laboratory under this subsection and require that the 3 laboratory report testing requiring a test at harvest and a 3 test at final processing. The possession by a laboratory of 3 medical marijuana shall be a lawful use. 3 (b) Stability testingA laboratory shall perform stability 4 testing to ensure the medical marijuana product by a laboratory and 4 approve a laboratory and requires that and a sample from each 4 medical marijuana produced by the grower/processor. The department shall 4 approve a laboratory and requiring a test at harvest and a 4 test at final processing the possession by a laboratory of 4 medical marijuana product derived from a harvest batch and 4 are proved under subsection (a) from each process lot 4 to perform stability testing under the following conditions: 4 (c) he medical marijuana product is stabil in inventory 4 to perform stability testing under the following conditions:</pre>		<u>collect</u> , handle and conduct tests on medical marijuana samples
 * ** "Cooperative laboratory." A public or private independent laboratory that identifies, collects, handles and conducts tests on medical marijuana samples on behalf of the department. The term does not include an approved laboratory. * * * "Independent laboratory." A laboratory that: (1) Is not owned, operated or affiliated with a medical marijuana organization. (2) Does not employ a principal, financial backer. operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability 		from a grower/processor, as part of the quality assurance
⁷ <u>"Cooperative laboratory." A public or private independent</u> <u>laboratory that identifies, collects, handles and conducts tests</u> on medical marijuana samples on behalf of the department. The <u>term does not include an approved laboratory.</u> * * * <u>"Independent laboratory." A laboratory that:</u> <u>(1) Is not owned, operated or affiliated with a medical</u> marijuana organization. (2) Does not employ a principal, financial backer, operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection arequire that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical mariguana product's potency and purity. A grower/processor shall retain a sample from each arequest that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory		testing and on medical marijuana samples from the department.
laboratory that identifies, collects, handles and conducts tests on medical marijuana samples on behalf of the department. The term does not include an approved laboratory. * * * "Independent laboratory." A laboratory that: (1) Is not owned, operated or affiliated with a medical marijuana organization. (2) Does not employ a principal, financial backer, operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * (c) Access[Information] Except as provided in section. 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana product derived from a harvest batch and purity. A grower/processor shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall perform stability testing to ensure the medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory.		* * *
8 laboratory that identifies, collects, handles and conducts tests 9 on medical marijuana samples on behalf of the department. The term does not include an approved laboratory. * * * "Independent laboratory." A laboratory that: 11 is not owned, operated or affiliated with a medical marijuana organization. 12 Does not employ a principal, financial backer, 13 operator or employee of a medical marijuana organization. 14 is recognized by an accreditation body to test and 15 evaluate products to an established product safety standard 16 evaluate products to an established product safety standard 17 free from commercial, financial or other pressures that may 18 influence the results of the testing and evaluation process. 18 * * * 18 Section 2. Sections 701(c) and 704 of the act are amended to 19 read: 10 evaluate products racking. 10 evaluate product safety standard 10 free from commercial, financial or other pressures that may 10 influence the results of the testing and evaluation process. 10 * * * 10 c) Access[Information] Except as provided in section 10 (1), information maintained in electronic tracking systems 10 under subsection (a) shall be confidential and not subject to 10 the act of February 14, 2008 (P.L.6, No.3), known as the Right- 10 to-Know Law. 11 * * * 12 Section 704. [Laboratory.] Laboratories. 12 [(a) General testingA grower/processor shall contract 13 with one or more independent laboratories to test the medical 14 approve a laboratory under this subsection and require that the 12 laboratory report testing results in a manner as the department shall 13 approve a laboratory under this subsection and require that the 13 aboratory report testing results in a manner as the department 14 approve a laboratory under this subsection and require that the 14 aboratory approved under subsection (a) from each process lot 14 test at final processing. The possession by a laboratory of 19 medical marijuana product derived from a harvest batch and 19 request that a sample be identified and collected by a		"Cooperative laboratory." A public or private independent
9 on medical marijuana samples on behalf of the department. The term does not include an approved laboratory. *** "Independent laboratory." A laboratory that: (1) Is not owned, operated or affiliated with a medical marijuana organization. (2) Does not employ a principal, financial backer, operator or employee of a medical marijuana organization. (3) Is recornized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * ** Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. * ** (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana produced by the grower/processor shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory		laboratory that identifies, collects, handles and conducts tests
<pre>10 term does not include an approved laboratory. * ** * **</pre>		on medical marijuana samples on behalf of the department. The
<pre>11 *** 12 "Independent laboratory." A laboratory that: 13 (1) Is not owned, operated or affiliated with a medical 14 mariluana organization. 15 (2) Does not employ a principal, financial backer, 16 operator or employee of a medical mariluana organization. 17 (3) Is recognized by an accreditation body to test and 18 evaluate products to an established product safety standard 19 free from commercial, financial or other pressures that may 10 influence the results of the testing and evaluation process. 11 * ** 12 (c) Access[Information] Except as provided in section 13 read: 14 Jack Section 701. Electronic tracking. 15 * ** 16 (c) Access[Information] Except as provided in section 17 704(1), information maintained in electronic tracking systems 18 under subsection (a) shall be confidential and not subject to 19 the act of February 14, 2008 (P.L.6, No.3), known as the Right- 10 to-Know Law. 11 * ** 12 Section 704. [Laboratory.] Laboratories. 13 [(a) General testingA grower/processor shall contract 14 with one or more independent laboratories to test the medical 15 marijuana produced by the grower/processor. The department 16 shall determine, including requiring a test at harvest and a 17 testing to ensure the medical marijuana produced by the grower/processor by a laboratory of 18 medical marijuana shall be a lawFul use. 19 (b) Stability testingA laboratory shall perform stability 19 testing to ensure the medical marijuana product's potency and 19 purity. A grower/processor shall retain a sample from each 19 medical marijuana product derived from a harvest batch and 19 request that a sample be identified and collected by a 11 laboratory approved under subsection (a) from each process lot 12 to perform stability testing under the following conditions: 13 (1) The medical marijuana product is still in inventory 14 (2) The medical marijuana product is still in inventory 15 (1) The medical marijuana product is still in inventory 16 (1) The medical marijuana product is still in inventory 16 (1) The medical</pre>		term does not include an approved laboratory.
13(1) Is not owned, operated or affiliated with a medical14marijuana organization.15(2) Does not employ a principal, financial backer,16operator or employee of a medical marijuana organization.17(3) Is recognized by an accreditation body to test and18evaluate products to an established product safety standard19free from commercial, financial or other pressures that may11influence the results of the testing and evaluation process.12Section 2. Sections 701(c) and 704 of the act are amended to13read:24Section 701. Electronic tracking.25* * *26(c) Access[Information] Except as provided in section27704(1), information maintained in electronic tracking systems28under subsection (a) shall be confidential and not subject to29the act of February 14, 2008 (P.L.6, No.3), known as the Right-20to-Know Law.21* * *22Section 704. [Laboratory.] Laboratories.33[(a) General testingA grower/processor shall contract34with one or more independent laboratories to test the medical35marijuana produced by the grower/processor. The department shall36approve a laboratory under this subsection and require that the37laboratory report testing requiring a test at harvest and a38test at final processing. The possession by a laboratory of39medical marijuana product derived from a harvest batch and40medical marijuana product s		
 (1) Is not owned, operated or affiliated with a medical marijuana organization. (2) Does not employ a principal, financial backer. operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a testing to ensure the medical marijuana product's potency and purity. A grower/processor shall perform stability testing to ensure the medical marijuana product be and the arijuana product derived from a harvest batch and feature that a sample be identified and collected by a 		"Independent laboratory." A laboratory that:
 marijuana organization. (2) Does not employ a principal, financial backer, operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. * * * Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a testing to ensure the medical marijuana product's potency and purity. A grower/processor shall perform stability testing to ensure the medical marijuana product be actived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (b) The medical marijuana product is still in inventory 	13	(1) Is not owned, operated or affiliated with a medical
 operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 2. Sections 701(c) and 704 of the act are amended to read: section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to te act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana produced be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana produced be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory 	14	marijuana organization.
16 operator or employee of a medical marijuana organization. (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. (a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana produced by the retain a sample from each approve that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory (1) The medical marijuana product is still in inventory	15	(2) Does not employ a principal, financial backer,
 (3) Is recognized by an accreditation body to test and evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. *** Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. *** (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. *** Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each approve that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory 	16	operator or employee of a medical marijuana organization.
 evaluate products to an established product safety standard free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. * * * Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory 	17	(3) Is recognized by an accreditation body to test and
free from commercial, financial or other pressures that may influence the results of the testing and evaluation process. *** Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. *** (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	18	evaluate products to an established product safety standard
<pre>influence the results of the testing and evaluation process. * * * * Section 2. Sections 701(c) and 704 of the act are amended to read: Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law.</pre>	19	free from commercial, financial or other pressures that may
 22 Section 2. Sections 701(c) and 704 of the act are amended to 23 read: 24 Section 701. Electronic tracking. 25 * * * 26 (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems 28 under subsection (a) shall be confidential and not subject to 29 the act of February 14, 2008 (P.L.6, No.3), known as the Right- 20 to-Know Law. 31 * * * 32 Section 704. [Laboratory.] Laboratories. 33 [(a) General testingA grower/processor shall contract 34 with one or more independent laboratories to test the medical 35 marijuana produced by the grower/processor. The department shall 36 approve a laboratory under this subsection and require that the 37 laboratory report testing results in a manner as the department 38 shall determine, including requiring a test at harvest and a 39 test at final processing. The possession by a laboratory of 40 medical marijuana shall be a lawful use. 41 (b) Stability testingA laboratory shall perform stability 42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory 	20	influence the results of the testing and evaluation process
read: read: Section 701. Electronic tracking. * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product derived from a harvest batch and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	21	* * *
<pre>23 read: 24 Section 701. Electronic tracking. 25 * * * 26 (c) Access[Information] Except as provided in section 27 704(1), information maintained in electronic tracking systems 28 under subsection (a) shall be confidential and not subject to 29 the act of February 14, 2008 (P.L.6, No.3), known as the Right- 30 to-Know Law. 31 * * * 32 Section 704. [Laboratory.] Laboratories. 33 [(a) General testingA grower/processor shall contract 34 with one or more independent laboratories to test the medical 35 marijuana produced by the grower/processor. The department shall 36 approve a laboratory under this subsection and require that the 37 laboratory report testing results in a manner as the department 38 shall determine, including requiring a test at harvest and a 39 test at final processing. The possession by a laboratory of 40 medical marijuana shall be a lawful use. 41 (b) Stability testingA laboratory shall perform stability 42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory</pre>	22	Section 2. Sections 701(c) and 704 of the act are amended to
<pre>25 * * * 26 (c) Access[Information] Except as provided in section 27 704(1), information maintained in electronic tracking systems 28 under subsection (a) shall be confidential and not subject to 29 the act of February 14, 2008 (P.L.6, No.3), known as the Right- 30 to-Know Law. 31 * * * 32 Section 704. [Laboratory.] Laboratories. 33 [(a) General testingA grower/processor shall contract 34 with one or more independent laboratories to test the medical 35 marijuana produced by the grower/processor. The department shall 36 approve a laboratory under this subsection and require that the 37 laboratory report testing requiring a test at harvest and a 39 test at final processing. The possession by a laboratory of 40 medical marijuana shall be a lawful use. 41 (b) Stability testingA laboratory shall perform stability 42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory</pre>	23	read:
 * * * (c) Access[Information] Except as provided in section 704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory 	24	Section 701. Electronic tracking.
704(1), information maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each addical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	25	
27 <u>704(1), information</u> maintained in electronic tracking systems under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * 2 Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	26	(c) Access[Information] Except as provided in section
<pre>under subsection (a) shall be confidential and not subject to the act of February 14, 2008 (P.L.6, No.3), known as the Right- to-Know Law. * * * Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory</pre>	27	704(1), information maintained in electronic tracking systems
<pre>29 the act of February 14, 2008 (P.L.6, No.3), known as the Right- 30 to-Know Law. 31 * * * 32 Section 704. [Laboratory.] Laboratories. 33 [(a) General testingA grower/processor shall contract 34 with one or more independent laboratories to test the medical 35 marijuana produced by the grower/processor. The department shall 36 approve a laboratory under this subsection and require that the 37 laboratory report testing results in a manner as the department 38 shall determine, including requiring a test at harvest and a 39 test at final processing. The possession by a laboratory of 40 medical marijuana shall be a lawful use. 41 (b) Stability testingA laboratory shall perform stability 42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory</pre>	28	under subsection (a) shall be confidential and not subject to
to-Know Law. 1 * * * 32 Section 704. [Laboratory.] Laboratories. 33 [(a) General testingA grower/processor shall contract 34 with one or more independent laboratories to test the medical 35 marijuana produced by the grower/processor. The department shall 36 approve a laboratory under this subsection and require that the 37 laboratory report testing results in a manner as the department 38 shall determine, including requiring a test at harvest and a 39 test at final processing. The possession by a laboratory of 40 medical marijuana shall be a lawful use. 41 (b) Stability testingA laboratory shall perform stability 42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	29	the act of February 14, 2008 (P.L.6, No.3), known as the Right-
Section 704. [Laboratory.] Laboratories. [(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	30	to-Know Law.
[(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	31	* * *
[(a) General testingA grower/processor shall contract with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	32	Section 704. [Laboratory.] Laboratories.
with one or more independent laboratories to test the medical marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	33	[(a) General testingA grower/processor shall contract
35 marijuana produced by the grower/processor. The department shall approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	34	with one or more independent laboratories to test the medical
approve a laboratory under this subsection and require that the laboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	35	marijuana produced by the grower/processor. The department shall
Iaboratory report testing results in a manner as the department shall determine, including requiring a test at harvest and a test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	36	approve a laboratory under this subsection and require that the
38 shall determine, including requiring a test at harvest and a 39 test at final processing. The possession by a laboratory of 40 medical marijuana shall be a lawful use. 41 (b) Stability testingA laboratory shall perform stability 42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	37	laboratory report testing results in a manner as the department
test at final processing. The possession by a laboratory of medical marijuana shall be a lawful use. (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory	38	shall determine, including requiring a test at harvest and a
40 medical marijuana shall be a lawful use. 41 (b) Stability testingA laboratory shall perform stability 42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	39	test at final processing. The possession by a laboratory of
 (b) Stability testingA laboratory shall perform stability testing to ensure the medical marijuana product's potency and purity. A grower/processor shall retain a sample from each medical marijuana product derived from a harvest batch and request that a sample be identified and collected by a laboratory approved under subsection (a) from each process lot to perform stability testing under the following conditions: (1) The medical marijuana product is still in inventory 	40	medical marijuana shall be a lawful use.
42 testing to ensure the medical marijuana product's potency and 43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	41	
43 purity. A grower/processor shall retain a sample from each 44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	42	testing to ensure the medical marijuana product's potency and
44 medical marijuana product derived from a harvest batch and 45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	43	purity. A grower/processor shall retain a sample from each
45 request that a sample be identified and collected by a 46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	44	medical marijuana product derived from a harvest batch and
46 laboratory approved under subsection (a) from each process lot 47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory	45	request that a sample be identified and collected by a
47 to perform stability testing under the following conditions: 48 (1) The medical marijuana product is still in inventory		laboratory approved under subsection (a) from each process lot
48 (1) The medical marijuana product is still in inventory		to perform stability testing under the following conditions.
(=, the measure product is still in them of y		(1) The medical marijuana product is still in inventory
I A A A A SUCHSALV IN THIS COMMONWAATT AS determined by the	49	at a dispensary in this Commonwealth as determined by the
50 seed-to-sale system.		seed-to-sale system.
51 (2) The stability testing is done at six-month intervals		

AUX 1001

1

1	for the duration of the expiration date period as listed on
2	the medical marijuana product and once within six months of
3	the expiration date.]
4	(a) Application and approval The following apply:
5	(1) An owner or operator of an independent laboratory
6	may apply, in the form and manner prescribed by the
7	department, for approval to test medical marijuana in
	accordance with the medical marijuana program.
8	(2) A nonrefundable initial application fee in the
9	amount of \$250 shall be paid by certified check or money
10	
11	<u>order.</u> (3) The department may designate the laboratory as an
12	(3) The department may designate the laboratory as an approved laboratory under this subsection if the department
13	approved laboratory under this subsection if the department
14	determines that an independent laboratory is financially and
15	professionally suitable to conduct testing required under
16	this act. Nothing in this subsection shall be deemed to
17	require the department to issue an approval to an independent
18	laboratory.
19	(4) An approval issued by the department to an
20	independent laboratory is valid:
21	(i) For two years from the date of issuance.
22	(ii) Only for the location specified in the
23	application and approval notice.
24	(5) An annual registration fee of \$125 shall be paid by
25	each approved laboratory.
26	(6) Fees payable under this section shall be deposited
27	into the fund.
28	(b) Compliance testing A grower/processor shall contract
29	with approved laboratories as required by the department to test
30	the medical marijuana produced by the grower/processor. The
31	following shall apply:
32	(1) The department shall establish uniform medical
33	marijuana testing standards and require that the approved
34	laboratory report testing results in a manner as the
35	department shall determine, including:
36	(i) Requiring a test at harvest and a final
37	processing.
38	(ii) Retesting of failed test results.
39	(2) A grower/processor may engage a single approved
40	laboratory to perform both the harvest lot and finished
41	product testing, or a grower/processor may engage more than
42	one approved laboratory to complete the harvest testing and
43	final product testing.
44	(c) Stability testing An approved laboratory shall perform
45	stability testing to ensure the medical marijuana product's
46	potency and purity. A grower/processor shall retain a sample
47	from each medical marijuana product derived from a harvest batch
48	and request that a sample be identified and collected by an
49	approved laboratory from each process lot to perform stability
50	testing under the following conditions:
51	(1) The medical marijuana product is still in inventory

1	<u>at a dispensary in this Commonwealth as determined by the</u>
2	seed-to-sale system.
3	(2) The stability testing is done at six-month intervals
4	for the duration of the expiration date period as listed on
5	the medical marijuana product and once within six months of
6	the expiration date.
7	(3) The stability testing results shall be reported to
8	the department.
9	(d) Research and development testing An approved
10	laboratory may collect samples from a grower/processor for
11	research and development if requested. Test results for research
12	and development shall be reported to the department. Testing for
13	research and development shall not be a replacement for
14	compliance testing.
15	(e) Audit testing The department, in its sole discretion,
16	may conduct audit testing of medical marijuana samples collected
17	from a grower/processor facility and medical marijuana products
18	found at a dispensary facility using a cooperative laboratory or
19	approved laboratory to identify, collect, handle and test the
20	medical marijuana on the department's behalf.
21	(f) Standard operating proceduresThe following shall
22	apply:
23	(1) An approved laboratory shall maintain written
24	standard operating procedures for each of the following:
25	(i) All sampling and testing procedures, including
26	compliance testing, stability testing, research and
27	development testing and quality assurance testing.
28	(ii) Quality control.
29	(iii) Any other operation as determined by the
30	<u>department.</u>
31	(2) An independent laboratory applying to be an approved
32	laboratory under subsection (a) shall submit the laboratory's
33	standard operating procedures to the department as part of
34	the independent laboratory's application.
35	(3) An approved laboratory shall, within 30 days of the
36	effective date of this paragraph, submit its standard
37	operating procedures to the department.
38	(4) An approved laboratory shall notify the department
39	in writing of any modifications to its standard operating
40 41	procedures no less than 30 days prior to the modification.
41	(g) Enforcement procedures The department shall conduct
42	announced and unannounced inspections or investigations to
43	determine an approved laboratory's compliance with its standard
44 45	operating procedures and this act. The department may require
45 46	the approved laboratory to submit and adhere to a corrective
46	action plan following an inspection.
47 48	(h) Accreditation body The department may engage with an
48 49	accreditation body to fulfill the requirements under this
49 50	section.
51	(i) Quality assurance testing The following shall apply:
JT	(1) The department shall coordinate testing for quality

1

1	assurance purposes related to the department and compliance
2	by each approved laboratory no less than once a year
3	beginning January 1 after the effective date of this
4	paragraph.
5	(2) The quality assurance testing may be announced or
6	unannounced.
7	(3) Any fees for conducting tests as part of the quality
8	assurance testing shall be the responsibility of each
9	approved laboratory. The fees associated with the cost of the
10	medical marijuana samples submitted as part of the testing
11	shall be waived.
12	(4) A test issued by an accreditation body as required
13	solely to maintain accreditation shall not fulfill the
14	requirements of this subsection.
15	(5) Nothing shall prohibit the department from
16	coordinating quality assurance testing more than once within
17	a calendar year.
18	(6) If the department determines that an approved
19	laboratory's test results are unsatisfactory, the department
20	shall initiate an investigation which may include the
21	following:
22	(i) Additional testing, as needed, to understand the
23	causes for the anomalies and unanticipated errors.
24	(ii) A review of the approved laboratory's standard
25	operating procedures.
26	(iii) An inspection of the approved laboratory's
27	facility, transportation vehicles, equipment,
28	instruments, tools and physical or electronic materials.
29	(iv) Interviews with the personnel, staff, directors
30	or other responsible parties of the approved laboratory.
31	(v) The approved laboratory submitting a corrective
32	action plan to the department for review. The following
33	shall apply:
34	(A) The department shall approve or deny a
35	corrective action plan within 30 days of receipt of
36	the plan.
37	(B) The department may, in its sole discretion,
38	allow the approved laboratory to submit a revised
39	corrective action plan based on the reasons for the
40	denial of the plan.
41	(C) The department shall approve or deny a
42	revised corrective action plan within 30 days.
43	(D) The plan shall be implemented within 30 days
44	of the approval of the department.
45	(j) Lawful possession The possession of medical marijuana
46	by an approved laboratory or cooperative laboratory to conduct
47	compliance testing, stability testing, audit testing and quality
48	assurance testing shall be lawful use.
49	(k) Violations In addition to any other requirements, the
50	following shall be considered to be violations of this section
51	and may result in penalties under section 1308(b):

2024/90LKK/HB2208A04176

1	(1) Failure to comply with the department as part of an
2	inspection or investigation.
3	(2) Failure to submit a corrective action plan as
4	required by the department.
5	(3) Failure to implement a corrective action plan within
6	<u>30 days of approval by the department.</u>
7	(4) Failure to participate in the required quality
8	assurance testing.
9	(5) Failure to produce:
10	<u>(i) Test results.</u>
11	(ii) Satisfactory test results as part of the
12	quality assurance testing.
13	(1) Sanctions The department may revoke or suspend the
14	<u>approval to test medical marijuana of an approved laboratory</u>
15	found to be in violation of this act or a regulation promulgated
16	under this act, violation of an order issued under this act or a
17	regulation promulgated under this act or for conduct or activity
18	which would have disgualified the approved laboratory from
19	receiving approval to test medical marijuana.
20	(m) Testing data and trend analysis The following shall
21	apply:
22	(1) An owner or operator of each approved laboratory
23	shall ensure that the laboratory enters all of the following
24	testing results into the seed-to-sale tracking system:
25	(i) Compliance testing.
26 27	(ii) Stability testing.
27	(iii) Research and development testing.
20 29	(iv) Quality assurance testing.
30	(2) The department may utilize the test results entered
31	by the approved laboratory for the following purposes:
32	(i) To conduct trend analysis for laboratory
33	oversight and compliance.
34	(ii) To review functionality of testing standards and methods.
35	
36	<u>(iii) To ensure compliance of medical marijuana</u> products.
37	
38	(iv) To ensure compliance by grower/processors. (v) To release de-identified data to academic
39	clinical research centers for research purposes only.
40	(vi) To compile and aggregate testing information to
41	post on the department's publicly accessible Internet
42	website.
43	(vii) To aid the department in any aspect of its
44	regulatory efforts, including administrative action.
45	(n) Accreditation The department shall determine the scope
46	of the accreditation an approved laboratory must receive and
47	maintain. The department shall provide an approved laboratory
48	reasonable time to receive any additional accreditation beyond
49	the laboratory's most recent certificate of accreditation.
50	(o) State testing laboratory The department may establish
51	and maintain a State testing laboratory. A State testing

2024/90LKK/HB2208A04176

2

1	laboratory under this section shall be responsible for all of
2	the following:
3	(1) Developing and maintaining a medical marijuana
4	laboratory reference library that contains testing
5	methodologies, including all of the following:
6	(i) Potency.
7	(ii) Homogeneity.
8	(iii) Detection of contaminants and the quantity of
9	those contaminants.
10	(iv) Solvents.
11	(2) Establishing standard operating procedures for
12^{11}	sample collection, preparation and analysis of medical
13	marijuana by approved laboratories.
	(3) Conducting proficiency testing of approved
14	
15	<u>laboratories.</u> (4) Remediation of problems with approved laboratories.
16	(4) Remediation of problems with approved laboratories. (5) Conducting compliance testing and audit testing on
17	(5) Conducting compliance testing and addit testing on
18	medical marijuana samples analyzed by approved testing
19	laboratories.
20	(p) MaterialsApproved laboratories shall provide materials to the State testing laboratory reference library.
21	(q) Powers and duties of department The department shall:
22	
23	
24	conduct the requirements of this section.
25	(2) Within 90 days of the effective date of this
26	paragraph, promulgate temporary regulations in accordance
27	with the following:
28	(i) In order to facilitate the prompt implementation
29	of this section, the department shall have the authority
30	to promulgate temporary regulations which shall expire
31	not later than two years following the publication of the
32	temporary regulations in the Pennsylvania Bulletin under
33	subparagraph (iii) and on the department's publicly
34	accessible Internet website.
35	(ii) The department may promulgate temporary
36	regulations not subject to:
37	(A) Sections 201, 202, 203, 204 and 205 of the
38	act of July 31, 1968 (P.L.769, No.240), referred to
39	as the Commonwealth Documents Law.
40	(B) Section 204(b) of the act of October 15,
41	1980 (P.L.950, No.164), known as the Commonwealth
42	Attorneys Act.
43	(C) The act of June 25, 1982 (P.L.633, No.181),
44	known as the Regulatory Review Act.
45	(iii) Within 90 days of the effective date of this
46	paragraph, the department shall transmit the temporary
47	regulations to the Legislative Reference Bureau for
48	publication in the next available issue of the
49	Pennsylvania Bulletin.
50	(iv) The board's authority to adopt temporary
51	regulations under subparagraph (i) shall expire two years

after publication of the temporary regulations. 1 2 Regulations adopted after this period shall be promulgated as provided by law. 3 4 (3) Within 90 days of submitting the temporary 5 regulations to the Legislative Reference Bureau, the department shall issue guidance to accompany the temporary 6 7 regulations. Section 3. Section 1201(b), (d), (e), (g), (h) and (i) of 8 the act is amended and subsection (a) is amended by adding a 9 10 paragraph to read: Section 1201. Advisory board. 11 Establishment. -- The Medical Marijuana Advisory Board is 12 (a) 13 established within the department. The advisory board shall 14 consist of the following members: * * * 15 (10) One member appointed by the Governor, who shall 16 have experience and expertise in laboratory science and shall 17 not be affiliated with, contracted with, owned by, operated 18 by or financed by an approved laboratory or medical marijuana 19 20 organization. Terms.--Except as provided under subsection (g), the 21 (b) members appointed under subsection (a) (8) [and], (9) and (10) 22 shall serve a term of four years or until a successor has been 23 appointed and qualified, but no longer than six months beyond 24 25 the four-year period. * * * 26 (d) Voting; quorum. -- The members under subsection (a) (1), 27 (2), (3), (4), (5), (6) and (7) shall serve ex officio and <u>all</u> 28 members shall have voting rights. A majority of the members 29 shall constitute a quorum for the purpose of organizing the 30 advisory board, conducting its business and fulfilling its 31 duties. A vote of the majority of the members present shall be 32 sufficient for all actions of the advisory board unless the 33 34 bylaws require a greater number. (e) Attendance. -- A member of the advisory board appointed 35 under subsection (a)(8) $[or]_{\mathcal{L}}$ (9) or (10) who fails to attend 36 three consecutive meetings shall forfeit his seat unless the 37 secretary, upon written request from the member, finds that the 38 39 member should be excused from a meeting for good cause. A member 40 who cannot be physically present may attend meetings via electronic means, including video conference. 41 42 * * * (g) Initial terms. -- The initial terms of members appointed 43 44 under subsection (a)(8) [and], (9) and (10) shall be for terms 45 of one, two, three or four years, the particular term of each 46 member to be designated by the secretary at the time of 47 appointment. All other members shall serve for a term of four 48 years. 49 Vacancy.--In the event that any member appointed under (h) 50 subsection (a)(8) [or], (9) or (10) shall die or resign or otherwise become disqualified during the member's term of 51

2

office, a successor shall be appointed in the same way and with 1 the same qualifications as set forth in this section and shall 2 3 hold office for the unexpired term. An appointed member of the advisory board shall be eligible for reappointment. 4 (i) Expenses.--A member appointed under subsection (a) (8) 5 [or], (9) or (10) shall receive the amount of reasonable travel, 6 hotel and other necessary expenses incurred in the performance 7 of the duties of the member in accordance with Commonwealth 8 regulations, but shall receive no other compensation for the 9 member's service on the board. 10 * * * 11 Section 4. This act shall take effect in 90 days. 12

-: -

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL No. 2208 Session of 2024

INTRODUCED BY FRANKEL, MADDEN, HILL-EVANS, HADDOCK, PARKER, SANCHEZ, KHAN, MAYES, CONKLIN AND OTTEN, APRIL 15, 2024

REFERRED TO COMMITTEE ON HEALTH, APRIL 15, 2024

AN ACT

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Amending the act of April 17, 2016 (P.L.84, No.16), entitled "An act establishing a medical marijuana program; providing for patient and caregiver certification and for medical marijuana organization registration; imposing duties on the Department of Health; providing for a tax on medical marijuana organization gross receipts; establishing the Medical Marijuana Program Fund; establishing the Medical Marijuana Advisory Board; establishing a medical marijuana research program; imposing duties on the Department of Corrections, the Department of Education and the Department of Human Services; and providing for academic clinical research centers and for penalties and enforcement," in medical marijuana controls, further providing for laboratory; and, in Medical Marijuana Advisory Board, further providing for advisory board.
16	The General Assembly of the Commonwealth of Pennsylvania
17	hereby enacts as follows:
18	Section 1. Section 704 of the act of April 17, 2016 (P.L.84,
19	No.16), known as the Medical Marijuana Act, is amended to read:
20	Section 704. Laboratory.
21	(a) General testingA grower/processor shall contract with
22	one or more independent laboratories to test the medical
23	marijuana produced by the grower/processor. The department shall
24	approve a laboratory under this subsection and require that the

laboratory report testing results in a manner as the department 1 2 shall determine, including requiring a test at harvest and a test at final processing. A grower/processor may engage a single 3 approved laboratory to perform both the harvest lot and finished 4 product testing or a grower/processor may engage more than one 5 approved laboratory to complete the harvest testing and final 6 7 product testing. The possession by a laboratory of medical 8 marijuana shall be a lawful use.

9 (b) Stability testing.--A laboratory shall perform stability 10 testing to ensure the medical marijuana product's potency and 11 purity. A grower/processor shall retain a sample from each 12 medical marijuana product derived from a harvest batch and 13 request that a sample be identified and collected by a 14 laboratory approved under subsection (a) from each process lot 15 to perform stability testing under the following conditions:

16 (1) The medical marijuana product is still in inventory
17 at a dispensary in this Commonwealth as determined by the
18 seed-to-sale system.

19 (2) The stability testing is done at six-month intervals 20 for the duration of the expiration date period as listed on 21 the medical marijuana product and once within six months of 22 the expiration date.

23 (c) Standard operating procedures.--

24 (1) An approved testing laboratory shall maintain
 25 written standard operating procedures for each of the
 26 following:

27 (i) Confirmation of the validity of results of
 28 testing.
 29 (ii) Quality control.

30 (iii) All sampling and testing procedures, including

20240HB2208PN2930

- 2 -

1	required safety tests.
2	(iv) Any other operation as determined by the
3	<u>department.</u>
4	(2) A laboratory applying for approval as a testing
5	laboratory shall submit its standard operating procedures to
6	the department as part of the laboratory's application.
7	(3) An approved testing laboratory shall submit its
8	standard operating procedures to the department at the
9	following time periods:
10	(i) for laboratories approved prior to the effective
11	date of this paragraph, within 30 days of the effective
12	date of this paragraph;
13	(ii) at each renewal of approval; and
14	(iii) within 30 days of a substantial change to the
15	standard operating procedures.
16	(4) The department shall enter and conduct a reasonable
17	inspection of an approved testing laboratory to ensure
18	adherence to the standard operating procedures at least
19	annually. The following shall apply:
20	(i) If the inspection results in the department
21	identifying gaps in the standard operating procedure, the
22	department shall submit its findings to the approved
23	testing laboratory.
24	(ii) Failure to adhere to corrective actions within
25	a reasonable time shall constitute a violation of this
26	act and may result in penalties under section 1308(b) or
27	(c). Nothing shall limit the department's ability to
28	suspend or revoke an approval issued to a laboratory as
29	prescribed in 28 Pa. Code Ch. 1171a (relating to
30	laboratories).

20240HB2208PN2930

- 3 -

1	(5) The department may engage with an independent
2	accreditation body to fulfill the requirements under this
3	subsection.
4	<u>(d) Validity of results testing</u>
5	(1) The department, in coordination with the Bureau of
6	Laboratories, shall ensure that approved testing
7	laboratories' results are valid no less than once a year
8	beginning on January 1 after the effective date of this
9	paragraph. The following apply:
10	(i) The department shall require approved testing
11	laboratories to participate in an established method used
12	to determine validity of results.
13	(ii) The department may engage an accredited
14	proficiency testing provider to fulfill subparagraph (i).
15	(iii) Nothing shall prohibit the department from
16	ensuring validity of results more than once within a
17	<u>calendar year.</u>
18	(iv) A test issued by an accredited proficiency
19	testing provider as required solely to maintain
20	accreditation shall not fulfill the requirements of this
21	subparagraph.
22	(2) If the results from an approved testing laboratory
23	are found to be invalid, the following actions shall be taken
24	by the department:
25	(i) A review of the approved testing laboratory's
26	standard operating procedures.
27	(ii) Additional testing, as needed, to understand
28	the cause for the anomalies and unanticipated errors.
29	(iii) The department may enter the approved testing
30	laboratory for further investigation and shall issue its

- 4 -

1	findings. The department may engage with an independent
2	accreditation body to fulfill the requirements under this
3	subparagraph.
4	(3) Failure to participate or failure to adhere to
5	corrective actions shall constitute a violation of this act
6	and may result in penalties under section 1308(b) or (c).
7	Nothing shall limit the department's ability to suspend or
8	revoke an approval issued to a laboratory as prescribed in 28
9	<u>Pa. Code Ch. 1171a.</u>
10	(e) Trend analysisThe department may utilize the seed-to-
11	sale tracking system to conduct trend analysis for laboratory
12	oversight.
13	(f) AccreditationThe department shall determine the scope
14	of accreditation an approved laboratory must receive and
15	maintain. The department shall provide an approved laboratory
16	reasonable time to receive any additional accreditation beyond
17	the laboratory's most recent certificate of accreditation.
18	(g) State testing laboratoryThe department may establish
19	and maintain a State testing laboratory. A State testing
20	laboratory under this subsection shall be responsible for:
21	(1) Developing and maintaining a medical marijuana
22	laboratory reference library that contains testing
23	methodologies in the areas of:
24	<u>(i) Potency.</u>
25	(ii) Homogeneity.
26	(iii) Detection of contaminants and the quantity of
27	those contaminants.
28	<u>(iv) Solvents.</u>
29	(2) Establishing standard operating procedures for
30	sample collection, preparation and analysis of medical

- 5 -

1	marijuana by approved testing laboratories.
2	(3) Conducting proficiency testing of approved testing
3	laboratories.
4	(4) Remediation of problems with approved testing
5	laboratories.
6	(5) Conducting compliance testing on medical marijuana
7	samples analyzed by approved testing laboratories.
8	(h) MaterialsApproved testing laboratories shall provide
9	materials to the State testing laboratory reference library.
10	(i) Memorandum of understandingThe department may enter
11	into a memorandum of understanding with the Department of
12	Agriculture to test medical marijuana at an existing State-run
13	laboratory if doing so would be a more economic and efficient
14	alternative to establishing a State testing laboratory under
15	subsection (g).
16	(j) Powers and duties of departmentThe department shall:
17	(1) Hire sufficient staff with the proper expertise to
18	conduct the requirements of this act.
19	(2) Promulgate regulations to facilitate the
20	implementation of this act and oversight of laboratories.
21	Section 2. Section 1201 of the act is amended to read:
22	Section 1201. Advisory board.
23	(a) EstablishmentThe Medical Marijuana Advisory Board is
24	established within the department. The advisory board shall
25	consist of the following members:
26	(1) The secretary or a designee.
27	(2) The Commissioner of the Pennsylvania State Police or
28	a designee.
29	(3) The chairman of the State Board of Pharmacy or a
30	designee.

20240HB2208PN2930

- 6 -

1 (4) The Commissioner of Professional and Occupational 2 Affairs or a designee. 3 (5) The Physician General or a designee. The president of the Pennsylvania Chiefs of Police 4 (6) 5 Association or a designee. The president of the Pennsylvania District Attorneys 6 (7)7 Association or a designee. 8 (8) One member to be appointed by each of the following, 9 which members shall be knowledgeable and experienced in 10 issues relating to care and treatment of individuals with a serious medical condition, geriatric or pediatric medicine or 11 12 clinical research: 13 (i) The Governor. The President pro tempore of the Senate. 14 (ii) 15 (iii) The Majority Leader of the Senate. 16 (iv) The Minority Leader of the Senate. 17 (v) The Speaker of the House of Representatives. 18 (vi) The Majority Leader of the House of 19 Representatives. 20 The Minority Leader of the House of (vii) 21 Representatives. 22 One member appointed by the Governor, who shall be a (9) 23 patient, a family or household member of a patient or a 24 patient advocate. 25 (10) One member appointed by the Governor, who shall 26 have experience and expertise in laboratory science. 27 Terms.--Except as provided under subsection (g), the (b) members appointed under subsection (a)(8) [and], (9) and (10) 28 29 shall serve a term of four years or until a successor has been appointed and qualified, but no longer than six months beyond 30 20240HB2208PN2930 - 7 -

1 the four-year period.

2 (c) Chair.--The secretary, or a designee, shall serve as3 chair of the advisory board.

(d) Voting; quorum. -- The members under subsection (a) (1), 4 (2), (3), (4), (5), (6) and (7) shall serve ex officio and shall 5 have voting rights. A majority of the members shall constitute a 6 quorum for the purpose of organizing the advisory board, 7 8 conducting its business and fulfilling its duties. A vote of the majority of the members present shall be sufficient for all 9 10 actions of the advisory board unless the bylaws require a 11 greater number.

(e) Attendance.--A member of the advisory board appointed under subsection (a)(8) [or], (9) or (10) who fails to attend three consecutive meetings shall forfeit his seat unless the secretary, upon written request from the member, finds that the member should be excused from a meeting for good cause. A member who cannot be physically present may attend meetings via electronic means, including video conference.

19 (f) Governance. -- The advisory board shall have the power to prescribe, amend and repeal bylaws, rules and regulations 20 21 governing the manner in which the business of the advisory board is conducted and the manner in which the duties granted to it 22 23 are fulfilled. The advisory board may delegate supervision of 24 the administration of advisory board activities to an 25 administrative secretary and other employees of the department 26 as the secretary shall appoint.

(g) Initial terms.--The initial terms of members appointed under subsection (a)(8) [and], (9) and (10) shall be for terms of one, two, three or four years, the particular term of each member to be designated by the secretary at the time of

20240HB2208PN2930

- 8 -

appointment. All other members shall serve for a term of four
 years.

3 (h) Vacancy.--In the event that any member appointed under 4 subsection (a)(8) [or], (9) or (10) shall die or resign or 5 otherwise become disqualified during the member's term of 6 office, a successor shall be appointed in the same way and with 7 the same qualifications as set forth in this section and shall 8 hold office for the unexpired term. An appointed member of the 9 advisory board shall be eligible for reappointment.

(i) Expenses.--A member appointed under subsection (a) (8)
[or], (9) or (10) shall receive the amount of reasonable travel,
hotel and other necessary expenses incurred in the performance
of the duties of the member in accordance with Commonwealth
regulations, but shall receive no other compensation for the
member's service on the board.

16 (j) Duties.--The advisory board shall have the following 17 duties:

18 (1) To examine and analyze the statutory and regulatory
19 law relating to medical marijuana within this Commonwealth.
20 (2) To examine and analyze the law and events in other
21 states and the nation with respect to medical marijuana.

(3) To accept and review written comments fromindividuals and organizations about medical marijuana.

24 (4) To issue written reports to the Governor, the Senate25 and the House of Representatives.

(5) The written reports under paragraph (4) shall
 include recommendations and findings as to the following:

(i) Whether to change the types of medical
professionals who can issue certifications to patients.
(ii) Whether to change, add or reduce the types of

20240HB2208PN2930

- 9 -

- 1 medical conditions which qualify as serious medical 2 conditions under this act.
- 3 (iii) Whether to change the form of medical
 4 marijuana permitted under this act.

5 (v) How to ensure affordable patient access to 6 medical marijuana.

7 (6) The written reports under this section shall be
8 adopted at a public meeting. The reports shall be a public
9 record under the act of February 14, 2008 (P.L.6, No.3),
10 known as the Right-to-Know Law.

11 Section 3. This act shall take effect in 90 days.

HOUSE OF REPRESENTATIVES DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No:SB0721 PN1147Committee:HealthSponsor:Schwank, JudyDate:4/17/2024

Prepared By:

Executive Director:

Erika Fricke (412) 422-1774 Erika Fricke

A. Brief Concept

Creates the Women, Infants and Children (WIC) State Advisory Board.

C. Analysis of the Bill

Recognizing the urgent need to reverse the decline in participation in the Women, Infant and Children federal nutrition program, Senate Bill 721 creates the Women, Infant and Children (WIC) state advisory board to advise the Department of Health (DOH) on strengthening the program. Details of the board are as follows:

Departmental advisory role:

The WIC Advisory Board, in addition to other topics related to the program, shall advise the department on:

- Program enhancements to increase the number of people enrolled in and using their WIC benefits and improve the connection between WIC benefits and other health and social and education benefits.
- Outreach initiatives to reach underserved parents who are eligible for the program, but not utilizing it.
- Technology to enhance program operations. This must include technology for reloading WIC cards remotely, telehealth for program participants, service coordination, fraud prevention and identity protection,
- Increasing the awareness and support around breastfeeding support services
- Increasing the number of stores that accept WIC in the Commonwealth.

Other duties of the board include:

- Reviewing the data on the number of eligible Pennsylvanians enrolled in WIC, and the number actually utilizing the benefit.
- Become knowledgeable about the WIC state plan and policy manual.
- Advise on best practices from other states.
- Consult with those other agencies or groups that work with DOH to fulfill the goals of the WIC program.

Board make-up and meetings:

The Secretary of Health will appoint 15 voting board members, each serving terms of three years. Members can serve only 6 months after their term expires and vacancies must be filled within 45 days.

The board members must include:

- (2) a pediatrician and another medical professional with expertise related to maternal health in underserved populations.
- (2) two advocates focused on food insecurity
- (2) two child or maternal health advocates
- (3) three WIC participants, each from a different region of the Commonwealth

- (2) two representatives from stores accepting WIC, ideally from an urban area and a rural area
- (3) three representatives from WIC agencies, each from a different region.
- (1) a breastfeeding expert

The Secretary of Health and the Director of the WIC program or designees, as well as two subject matter experts identified by DOH, shall be non-voting members of the board.

The Secretary or designee is Chair of the Board, but the vice-chair, selected by voting board members, will set the agenda.

Ten voting members are needed to achieve a quorum.

The board must meet monthly for the first six months of existence, and after that must meet quarterly.

Board members will not receive compensation but can be reimbursed for travel-related expenses.

If a conflict of interest occurs, a board member can't vote on that issue.

Effective Date:

60 days

G. Relevant Existing Laws

The Women, Infants and Children Nutrition Act of 1986 allowed state funds, administered by the Department of Health, to be added to the federal funds provided to the WIC program, in order to increase program participation. The administrative funds from the state must be used in part for an outreach program.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE BILL No. 721 Session of 2023

INTRODUCED BY SCHWANK, BROOKS, COSTA, AUMENT, HUGHES, KEARNEY, TARTAGLIONE, FONTANA, KANE, HAYWOOD, COMITTA, LAUGHLIN, CAPPELLETTI, BAKER, J. WARD, COLLETT, BREWSTER AND MUTH, JUNE 2, 2023

SENATOR BROOKS, HEALTH AND HUMAN SERVICES, AS AMENDED, OCTOBER 3, 2023

AN ACT

1 2	Establishing the Women, Infants and Children State Advisory Board.
3	The General Assembly finds and declares as follows:
4	(1) The Commonwealth intends to maximize the Federal
5	funding available for the Pennsylvania Special Supplemental
6	Nutrition Program for Women, Infants and Children by
7	maximizing participation and enrollment in the program to
8	support healthier pregnancies, maternal outcomes, births and
9	birth outcomes, improving health in pregnant women,
10	postpartum women, children and infants in this Commonwealth
11	and coordinating with other programs that support women,
12	infants and children.
13	(2) Immediate action is needed to halt the steady
14	decline in WIC participation and enrollment and the resultant
15	decrease in Federal funding and nutritional assistance for
16	Pennsylvania's lower-income women, infants and children, by

increasing the use of technology and administrative
 organization and by greater transparency in operation and use
 of Federal funding.

4 (3) It is necessary to steadily increase participation 5 and enrollment in programs that support women, infants and 6 children, eliminate enrollment barriers, coordinate and 7 connect with related programs and maximize technology to 8 improve maternal and infant birth outcomes and the health of 9 children eligible for participation in the program.

10 The General Assembly of the Commonwealth of Pennsylvania 11 hereby enacts as follows:

12 Section 1. Short title.

13 This act shall be known and may be cited as the WIC State 14 Advisory Board Act.

15 Section 2. Definitions.

16 The following words and phrases when used in this act shall 17 have the meanings given to them in this section unless the 18 context clearly indicates otherwise:

19 "Board." The Women, Infants and Children State Advisory20 Board established in section 3.

21 "Department." The Department of Health of the Commonwealth.
22 "Enrollment." The number of active WIC participants who are
23 eligible to receive food benefits.

24 "Food instrument." A voucher, check, electronic benefits 25 transfer (EBT) card, coupon or other document that is used by a 26 participant to obtain supplemental foods.

27 "Participation." The number of individuals who have received28 WIC food benefits on a food instrument.

29 "WIC." The Pennsylvania Special Supplemental Nutrition30 Program for Women, Infants and Children.

20230SB0721PN1147

- 2 -

1 Section 3. Establishment.

2 The Women, Infants and Children State Advisory Board is3 established in the department.

4 Section 4. Topics.

7

5 (a) Advising.--The board shall advise the department on the6 following topics:

(1) The operation of the programs, to:

8 (i) Increase enrollment and utilization of the9 programs.

10 (ii) Improve the quality of services to support
11 connections between WIC and comprehensive services to
12 address the social, health, educational and other needs
13 of pregnant individuals, mothers, infants and children.

14 (2) Outreach initiatives to increase participation and
 15 enrollment in the program, including any underserved
 16 populations.

17 (3) Technology improvements or enhancements for program18 operations, efficacy and efficiency, including:

19 (i) Incorporating the use of technology and
20 modernization tools that remove barriers for program
21 participants, including the potential to load benefits
22 remotely and purchase WIC benefits online.

(ii) Developing and maximizing the use of telehealth
technology for the increased convenience of program
participants.

(iii) Coordinating and collating services to improve
 efficiency and effectiveness of those services.

(iv) Establishing security measures to protect WIC
 participants' personal information and prevent fraudulent
 activity in the use of WIC benefits.

20230SB0721PN1147

- 3 -

1 (4) INCREASING AWARENESS AND SUPPORT OF WIC <---2 BREASTFEEDING SERVICES FOR WIC PARTICIPANTS. INCREASING ACCESS TO WIC-AUTHORIZED STORES FOR WIC 3 (5)PARTICIPANTS. 4 5 (b) Other topics. -- The board may advise the department on 6 other topics bearing on the program. Section 5. Duties. 7 8 The board shall have the following duties: 9 (1)Review current aggregate data on WIC eligibility and 10 participation and enrollment at the State level from the 11 department. 12 (2) Become familiar with the WIC Policy Manual and WIC 13 State plan. 14 (3) Advise on best practices that are used in other 15 states. 16 Consult with organizations and other agencies that (4) work with WIC participants in fulfilling duties under this 17 18 act. 19 (5) Advise the department on the topics enumerated in 20 section 4. 21 Section 6. Membership and meetings. 22 (a) Membership.--The board shall consist of the following members: 23 24 (1)The following individuals shall be ex officio 25 members of the board: 26 The Secretary of Health or a designee who shall (i) 27 be an employee of the department. 28 The Director of WIC or a designee who shall be (ii) 29 an employee of the department with specialized knowledge of WIC. 30

20230SB0721PN1147

- 4 -

1 (iii) Two subject matter experts, as determined by 2 the Secretary of Health or a designee. 3 (2)Remaining members of the board shall include the number of representatives from each of the following 4 5 categories as indicated, for a total of 14 15 remaining <--members: 6 7 (i) Two medical professionals with expertise in 8 serving women and children from underserved populations, <--ONE OF WHOM IS A PEDIATRIC PHYSICIAN. 9 10 (ii) Two advocates focused on addressing food 11 insecurity. 12 (iii) Two child or maternal advocates. 13 (iv) Three WIC participants, each representing a 14 different region of this Commonwealth. (v) One representative from two different WIC-15 16 authorized stores or representatives or designees of WIC-17 authorized stores, for a total of two, with preference 18 being for one representative from a store located in an 19 urban area and one representative from a store located in 20 a rural area, as determined by the Secretary of Health. 21 (vi) One representative from each of three different 22 WIC local agencies, for a total of three representatives, 23 each representing a different region of this 24 Commonwealth. 25 (VII) ONE INDIVIDUAL WHO IS AN EXPERT ON <---26 BREASTFEEDING. 27 (b) Chair .-- The Secretary of Health or the Secretary of 28 Health's designee shall serve as chair of the board. The 29 following apply: 30 (1) At the first board meeting, board members shall

20230SB0721PN1147

- 5 -

1 self-select a vice chair and secretary.

2 (2) The vice chair shall assist in the agenda creation3 and meeting organization.

4 (3) The Secretary of Health shall select a board member
5 to fill the vice chair's obligations in the vice chair's
6 absence.

7 (4) The secretary of the board shall capture and8 distribute meeting minutes.

9 (c) Quorum.--Ten board members under subsection (a)(2) shall 10 constitute a quorum.

(d) Voting.--Only board members under subsection (a) (2)
shall have voting rights. The vote of the majority of the quorum of board members shall prevail.

14 (e)

(e) Appointment and terms.--

(1) The Secretary of Health shall appoint members of the
board under subsection (a) (2) for staggered three-year terms,
as determined by the Secretary of Health, for a term not to
exceed three consecutive years.

19 (2) A board member whose term has expired shall continue
20 as a member of the board until a replacement has been
21 appointed. The member shall have full voting rights and count
22 for purposes of establishing a quorum. In no event shall a
23 member continue to serve on the board beyond six months from
24 the date of term expiration.

(3) Ex officio members or their designees shall serve so
long as the official continues to serve in an official
position.

(f) Vacancies.--Vacancies in the membership of the board shall be filled within 45 days of the vacancy in the same manner as provided for the original appointments.

20230SB0721PN1147

- 6 -

1 Staffing.--The board shall be staffed in collaboration (q) 2 with individuals from the department.

3 (h) Subcommittees. -- The board may create subcommittees of the board members to carry out specific tasks or research. 4 Subcommittees are to be created on an ad hoc basis and are not 5 to replace or interfere with the efforts of the board. 6

7 Meetings .-- The board shall meet in accordance with the (i) 8 following:

9 Members shall meet no fewer than four times per (1)10 year, on a quarterly basis, except that the board shall meet 11 every month for the first six months after the establishment 12 of the board and, thereafter for the remainder of the first 13 year, the board shall meet on a quarterly basis.

14 (2)The agenda for each meeting and all meeting minutes 15 shall be posted to the department's publicly accessible 16 Internet website.

Meetings must comply with the following: 17 (3)

18

(i) The act of February 14, 2008 (P.L.6, No.3), 19 known as the Right-to-Know Law.

20 65 Pa.C.S. Ch. 7 (relating to open meetings). (ii) 21 Section 7. Compensation and reimbursement.

22 Board members shall not be entitled to compensation for their 23 services as board members. Board members shall be entitled to 24 reimbursement in accordance with Commonwealth guidelines for 25 reasonable travel, lodging and other necessary expenses incurred 26 in the performance of their duties as board members.

27 Section 8. Conflict of interest.

Board members shall recuse themselves from discussions and 28 29 actions if a conflict of interest may exist.

Section 9. Effective date. 30

20230SB0721PN1147

- 7 -

1 This act shall take effect in 60 days.

HOUSE OF REPRESENTATIVES DEMOCRATIC COMMITTEE BILL ANALYSIS

Bill No: HR0397 PN2949 **Committee:** Health Sponsor: Oberlander, Donna Date: 4/29/2024

Prepared By:

Patrick O'Rourke (717) 787-4296,6711

Executive Director:

Erika Fricke

A. Brief Concept

House Resolution 397 recognizes the week of May 6-12, 2024 as "Women's Lung Health Week."

C. Analysis of the Bill

Lung cancer is a leading cause of cancer deaths in the United States:

- Accounts for 1 in 5 of all cancer deaths.
- More individuals die of lung cancer than colon, breast, and prostate cancers combined.
- Both small cell and non-small cell lung cancers combine for the second most common cancer in women in the United States.
- The lung cancer death rate in women has almost doubled over the past 40 years.
- Per American Cancer Society, the estimate for diagnosis of new lung cancer in U.S. women is approximately 118,270 cases resulting in 59,280 deaths.
- About 1 in 17 women will develop lung cancer in their lifetime, including for both smokers and nonsmokers.
- White women are 16% more likely to develop lung cancer than Black women.
- Black women are less likely to be diagnosed with lung cancer at an early stage when survival rates are the highest.
- In 2024, the American Lung Association celebrates 120 years of impact and leads the national initiative to defeat lung cancer.
- Public support for research funding results in new treatments and better methods of early detection.
- Lung cancer screening saves lives and advocacy and increased awareness will result in more high-risk individuals getting screened.

Effective Date:

N/A.

G. Relevant Existing Laws

N/A.

E. Prior Session (Previous Bill Numbers & House/Senate Votes)

N/A.

This document is a summary of proposed legislation and is prepared only as general information for use by the Democratic Members and Staff of the Pennsylvania House of Representatives. The document does not represent the legislative intent of the Pennsylvania House of Representatives and may not be utilized as such.

4/29/24, 1:07 PM

Bill Analysis - Preview

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE RESOLUTION No. 397 Session of 2024

INTRODUCED BY OBERLANDER, ROWE, MCNEILL, HEFFLEY, PICKETT, KINSEY, MALAGARI, SCHLOSSBERG, CURRY, CAUSER, CERRATO, NEILSON AND CONKLIN, APRIL 16, 2024

REFERRED TO COMMITTEE ON HEALTH, APRIL 16, 2024

A RESOLUTION

1 2	Recognizing the week of May 6 through 12, 2024, as "Women's Lung Health Week" in Pennsylvania.
3	WHEREAS, Lung cancer is by far the leading cause of cancer
4	deaths in the United States, accounting for about one in five of
5	all cancer deaths; and
6	WHEREAS, Each year, more people die of lung cancer than of
7	colon, breast and prostate cancers combined; and
8	WHEREAS, Lung cancer, both small cell and non-small cell, is
9	the second most common cancer in women in the United States; and
10	WHEREAS, The lung cancer death rate in women has almost
11	doubled over the past 40 years; and
12	WHEREAS, For 2024, the American Cancer Society's estimate for
13	the diagnosis of new lung cancer in women in the United States
14	is approximately 118,270, with lung cancer resulting in 59,280
15	deaths of women in the nation; and
16	WHEREAS, The chance that a woman will develop lung cancer in
17	her lifetime is about 1 in 17, including both smokers and

1 nonsmokers; and

2 WHEREAS, White women are about 16% more likely to develop 3 lung cancer than Black women; and

4 WHEREAS, Black women are less likely to be diagnosed with 5 lung cancer at an early stage when survival rates are the 6 highest; and

7 WHEREAS, While women have lower rates of lung cancer than 8 men, the lung cancer rate among women has been dropping only 9 during the past decade; and

10 WHEREAS, The American Lung Association celebrates 120 years 11 of impact in 2024 and leads the national initiative to defeat 12 lung cancer; and

13 WHEREAS, Public support for research funding will result in 14 new treatments and better methods of early detection; and 15 WHEREAS, Lung cancer screening saves lives and advocacy and 16 increased awareness will result in more high-risk individuals 17 getting screened; therefore be it

18 RESOLVED, That the House of Representatives recognize the 19 week of May 6 through 12, 2024, as "Women's Lung Health Week" in 20 Pennsylvania; and be it further

21 RESOLVED, That the House of Representatives encourage all 22 residents of this Commonwealth to learn more about the detection 23 and treatment of lung cancer.

- 2 -